CureVac ’s Covid-19 Vaccine Disappoints in Clinical Trial

A preliminary analysis showed that CureVac ’s mRNA vaccine had an efficacy of just 47 percent. “This is pretty devastating for them,” one expert said.

Source: NYT Health - June 16, 2021 Category: Consumer Health News Authors: Carl Zimmer Tags: Vaccination and Immunization Coronavirus (2019-nCoV) RNA (Ribonucleic Acid) CureVac GmbH your-feed-healthcare Source Type: news